Isabel Garau

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 120 citations

Breast Oncology, Medicine, Cancer Management +7

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

Eva Ciruelos, Patricia Villagrasa, Tomás Pascual et al. · Clinical Cancer Research · 2020 · 111 citations

Recent Changes in Breast Cancer Incidence in Spain, 1980–2004

Marina Pollán, Roberto Pastor‐Barriuso, Eva Ardanáz et al. · JNCI Journal of the National Cancer Institute · 2009 · 109 citations · Full text

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

Paolo Nucíforo, Tomás Pascual, Javier Cortés et al. · Annals of Oncology · 2017 · 107 citations

Predictive Model, Tumor Cellularity, Cancer Immunosurveillance +12

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Fara Brasó‐Maristany, Gaia Griguolo, Tomás Pascual et al. · Nature Communications · 2020 · 105 citations · Full text